[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 27, 1966

Vasodilator In Shock Gains Laboratory, Clinical Support

JAMA. 1966;196(13):27. doi:10.1001/jama.1966.03100260017005

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Investigators studying shock accompanying acute myocardial infarction report some increase in survival of dogs treated with a selective vasodilator.

In this study, at the University of Minnesota Medical School, shock was defined as "a 35% or greater reduction in blood pressure and a 50% or greater reduction in cardiac output and electrocardiographic evidence of ischemia," Ronald H. Dietzman, MD, told JAMAMedical News.

Phenoxybenzamine was the vasodilator used, Dr. Dietzman said, adding:

"Maintenance of blood pressure with vasopressors is logical in those cases of cardiogenic shock which have a normal or lowered total peripheral resistance. But in most cases of cardiogenic shock, total peripheral resistance is elevated. Consequently, we chose to evaluate the effect of a vasodilator..."

Richard C. Lillehei, MD, PhD; Gary W. Lyons, MD; and Jack H. Bloch, MD, are other members of the research team.

Diffuse myocardial infarctions were produced in 122 adult mongrel dogs by closed

First Page Preview View Large
First page PDF preview
First page PDF preview